Quest Diagnostics has taken the wraps off its plans at the ON3 campus in Nutley and Clifton, where it will build a 250,000-square-foot flagship laboratory facility that will become the largest in its portfolio.
New Jersey’s office market is riding high from a series of blockbuster leases over the summer, recording its highest quarterly increase in net absorption in two years.
Prism Capital Partners is poised to move forward with its redevelopment of five acres in downtown Woodbridge, where it’s planning a mixed-use project with more than 230 apartments.
Prism Capital Partners has launched nearly $10 million in roadway and utility upgrades at the former Hoffmann-LaRoche campus in Nutley and Clifton, as it prepares to welcome new tenants to the 116-acre redevelopment site.
I am convinced more than ever that forward-thinking New Jersey suburbs are poised for a comeback. Many city residents, especially those in their 20s and 60s will seek alternate residences. Towns that have invested in their infrastructure and assets for the long term and are ready to accommodate this exodus of consumers and their preferences will be able to compete for this wealth of talent and the resources they bring to the community.
For all the time we’ve spent highlighting New Jersey’s glut of sprawling, vacant corporate campuses, it’s easy to lose sight of just how many of them have been rescued in recent years by some of the state’s boldest and most inventive developers. Those success stories are worth telling, which is why we often do at Real Estate NJ. But there are underlying trends or nuances in some of those projects that don’t get as much attention on a day-to-day basis. Like how a crop of innovative, lesser-known biotech and pharmaceutical firms are backfilling space at the former research campuses of Sanofi and Hoffmann-LaRoche, helping to stabilize those sites as their new owners pursue larger redevelopment plans.
Despite years of consolidation by Big Pharma, New Jersey is one of a handful of markets that stand to gain from a promising growth trajectory for the U.S. life sciences sector.